Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: Evidence of etravirine cross-resistance

Ujjwal Neogi, Anita Shet, Ranjani Shamsundar, Maria L. Ekstrand

Research output: Contribution to journalArticlepeer-review

Abstract

Prevalence of etravirine genotypic resistance was assessed among 92 HIV-1C-infected patients failing nevirapine and efavirenz-based regimens from a cohort of 552 Indian patients. Overall, prevalence of etravirine cross-resistance identified using the Tibotec Weighted Score was 41% (31.5% intermediately-resistant and 9.8% fully-resistant). The most frequently described nonnucleoside reverse transcriptase inhibitor-associated mutations included Y181 (35.9%), K101 (20.7%), G190 (17.4%), and V108 (15.2%). The resistant group demonstrated higher viral load (P = 0.01) and longer duration of antiretroviral treatment (P = 0.03) compared with the susceptible group.

Original languageEnglish (US)
Pages (from-to)1123-1125
Number of pages3
JournalAIDS
Volume25
Issue number8
DOIs
StatePublished - May 15 2011
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: Evidence of etravirine cross-resistance'. Together they form a unique fingerprint.

Cite this